Magenta Therapeutics, Inc.
MGTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $6 |
| % Growth | 105.2% | -83.4% | -81.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 0% | 0% | 0% | 0% |
| R&D Expenses | $32 | $26 | $27 | $67 |
| G&A Expenses | $8 | $9 | $7 | $5 |
| SG&A Expenses | $8 | $9 | $7 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $41 | $35 | $34 | $72 |
| Operating Income | -$40 | -$35 | -$33 | -$83 |
| % Margin | -10,173.7% | -18,096.9% | -2,852.7% | -1,324.9% |
| Other Income/Exp. Net | $4 | $3 | $4 | $45 |
| Pre-Tax Income | -$37 | -$32 | -$30 | -$38 |
| Tax Expense | $0 | $0 | $0 | $9 |
| Net Income | -$37 | -$32 | -$30 | -$32 |
| % Margin | -9,284.1% | -16,388.1% | -2,537.5% | -518.6% |
| EPS | -9.41 | -8.1 | -7.55 | 13.02 |
| % Growth | -16.2% | -7.3% | -158% | – |
| EPS Diluted | -9.41 | -8.1 | -7.55 | 13.02 |
| Weighted Avg Shares Out | 4 | 4 | 4 | 4 |
| Weighted Avg Shares Out Dil | 4 | 4 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $3 | $4 | $9 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$4 |
| EBITDA | -$37 | -$35 | -$33 | -$36 |
| % Margin | -9,259.1% | -18,096.9% | -2,852.7% | -576.8% |